Fluoro-A-85380 demonstrated no mutagenic properties in in vivo rat micronucleus and Ames tests.

[1]  A. van Waarde,et al.  Mutagenic activity of a fluorinated analog of the beta-adrenoceptor ligand carazolol in the Ames test. , 2000, Nuclear medicine and biology.

[2]  J M Links,et al.  2-[18F]F-A-85380: a PET radioligand for alpha4beta2 nicotinic acetylcholine receptors. , 1999, Neuroreport.

[3]  C Crouzel,et al.  Imaging central nicotinic acetylcholine receptors in baboons with [18F]fluoro-A-85380. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  C Crouzel,et al.  Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors. , 1999, Journal of medicinal chemistry.

[5]  C. Crouzel,et al.  Characterization of the nicotinic ligand 2-[18F]fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine in vivo. , 1998, Life sciences.

[6]  D. Donnelly-roberts,et al.  Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice. , 1998, Bioorganic & medicinal chemistry letters.

[7]  E. London,et al.  6-[18F]Fluoro-A-85380: an in vivo tracer for the nicotinic acetylcholine receptor. , 1998, Nuclear medicine and biology.

[8]  E. London,et al.  2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. , 1998, Journal of medicinal chemistry.

[9]  A. van Waarde,et al.  Validation of S-1'-[18F]fluorocarazolol for in vivo imaging and quantification of cerebral beta-adrenoceptors. , 1998, European journal of pharmacology.

[10]  C. Crouzel,et al.  Synthesis of 2‐[18F]fluoro‐3‐[2(S)‐2‐azetidinylmethoxy]pyridine, a highly potent radioligand for in vivo imaging central nicotinic acetylcholine receptors , 1998 .

[11]  John L. Musachio,et al.  Synthesis of a radiotracer for studying nicotinic acetylcholine receptors: 2-[18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[18F]A-85380) , 1998 .

[12]  D. Donnelly-roberts,et al.  Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. , 1998, Journal of medicinal chemistry.

[13]  D. Donnelly-roberts,et al.  A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: In Vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand , 1996, Neuropharmacology.

[14]  D. Donnelly-roberts,et al.  Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. , 1996, Journal of medicinal chemistry.

[15]  A. van Waarde,et al.  (S,S)- and (S,R)-1'-[18F]fluorocarazolol, ligands for the visualization of pulmonary beta-adrenergic receptors with PET. , 1996, Nuclear medicine and biology.

[16]  K. Kellar,et al.  [3H]epibatidine labels nicotinic receptors in rat brain: an autoradiographic study. , 1995, The Journal of pharmacology and experimental therapeutics.

[17]  A. van Waarde,et al.  Myocardial and pulmonary uptake of S-1'-[18F]fluorocarazolol in intact rats reflects radioligand binding to beta-adrenoceptors. , 1995, European journal of pharmacology.

[18]  F. Miraldi,et al.  Specific beta-adrenergic receptor binding of carazolol measured with PET. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  R R Tice,et al.  In vivo rodent erythrocyte micronucleus assay. , 1994, Mutation research.

[20]  T Ohta,et al.  Recommendations for the performance of bacterial mutation assays. , 1994, Mutation research.

[21]  S. Arneric,et al.  Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain. , 1994, European journal of pharmacology.

[22]  A. Boobis,et al.  Report of British Toxicology Society/UK Environmental Mutagen Society Working Group. Dose setting in in vivo mutagenicity assays. , 1992 .

[23]  M. Berridge,et al.  Preparation and in vivo binding of [11C]carazolol, a radiotracer for the beta-adrenergic receptor. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[24]  B. Ames,et al.  Revised methods for the Salmonella mutagenicity test. , 1983, Mutation research.

[25]  F. D. de Serres,et al.  The Salmonella mutagenicity assay: recommendations. , 1979, Science.

[26]  B. Ames,et al.  Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. , 1975, Mutation research.

[27]  N. Kitteringham,et al.  Metabolism of fluorine-containing drugs. , 2001, Annual review of pharmacology and toxicology.

[28]  J S Fowler,et al.  Comparative studies of epibatidine derivatives [18F]NFEP and [18F]N-methyl-NFEP: kinetics, nicotine effect, and toxicity. , 1999, Nuclear medicine and biology.